Nuvation Bio is a clinical-stage company developing treatments focused on specific cancer types. Its primary program is IBTROZI, a medication targeting ROS1-positive lung cancer, while a second candidate called Safusidenib is undergoing late-stage testing for certain brain tumors carrying IDH1 mutations. The company was established in 2018 and operates from New York.

entry readiness 42 · WEAK SETUP · exit proximity 0

Value area 4.96–7.16 · 35% of 120d volume overhead · moderate overhead